Cue Health Makes De Novo Submission to FDA for Full Clearance of its Cue® Flu Molecular Test

Rhea-AI Summary

Cue Health (Nasdaq: HLTH) announced a de novo submission to the FDA for full clearance of its Cue® Flu Molecular Test, the first at-home flu test reviewed for safety and effectiveness. The clinical study indicated 99% accuracy compared to existing lab tests for influenza A&B. This test aims to facilitate early detection and treatment, aligning with Cue's strategy of innovation in diagnostics. The company's COVID-19 test remains under FDA de novo review. With over 250,000 Cue Readers in use, Cue Health is positioned as a leader in accessible health diagnostics.

Positive

• First FDA-reviewed at-home flu test submission.
• 99% accuracy in clinical studies compared to lab tests.
• Potential for early flu detection and treatment accessibility.
• Strong market presence with over 250,000 Cue Readers shipped.

Negative

• None.

SAN DIEGO, Sept. 1, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH) today announced that it has made a de novo submission to the U.S. Food and Drug Administration (FDA) for full clearance of the Cue® Flu Molecular Test for at-home and point-of-care (POC) use. There are currently no flu tests on the market for home use. FDA clearance of Cue's test would provide the public, for the first time, an at-home and POC molecular flu test that has been fully reviewed by the FDA for safety and effectiveness.

Clinical study results with the Cue Flu Molecular Test were favorable, demonstrating 99% accuracy¹ compared to FDA cleared molecular (PCR) laboratory tests for influenza A&B. The Cue Flu Molecular Test cartridge uses a lower nasal swab and is compatible with the Cue Reader, which communicates test results digitally via Bluetooth to a mobile device in approximately 25 minutes.

"This FDA submission for our Cue Flu Molecular Test is another important milestone on Cue's path to pioneer a new approach to diagnostics in homes, enterprises, and healthcare settings," said Ayub Khattak, Chairman and CEO of Cue Health. "Early detection and treatment can meaningfully improve health outcomes. There are multiple FDA-approved antiviral treatments for influenza available today, and we expect we will soon be able to promptly get these medications into the hands of patients who need them thanks to our recently launched Cue Care service."

Cue's molecular COVID-19 test, which is authorized by the FDA for home and POC use under an Emergency Use Authorization (EUA), is also currently under de novo review with the FDA. With an installed base of over a quarter million Cue Readers shipped to date, Cue's COVID-19 test has been used by millions of Americans. Cue is used by some of the nation's leading healthcare institutions, including Johns Hopkins Medicine, Mayo Clinic, Memorial Hermann, and UPMC Children's Hospital of Pittsburgh. Cue is also used by world-class organizations such as Major League Baseball, Google, the National Basketball Association, Bridgewater, among others.

About Cue Health
Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easier for individuals to access health information and places diagnostic information at the center of care. Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore's Health Sciences Authority. Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements". The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those related to the expected future diagnostic test menu and the factors discussed in the "Risk Factors" section of Cue's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 10, 2022. Any forward-looking statements contained in this press release are based on the current expectations of Cue's management team and speak only as of the date hereof, and Cue specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Cue's COVID-19 tests have not been FDA cleared or approved; but have been authorized by FDA and under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

1 With discordance analysis using a second FDA-cleared laboratory PCR test

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cue-health-makes-de-novo-submission-to-fda-for-full-clearance-of-its-cue-flu-molecular-test-301616412.html

SOURCE Cue Health Inc.

FAQ

What is the significance of Cue Health's FDA submission for the Cue Flu Molecular Test?

Cue Health's FDA submission aims to secure full clearance for the first at-home flu test, enhancing public access to effective flu diagnostics.

When was Cue Health's press release announcing the FDA submission issued?

The press release was issued on September 1, 2022.

What are the accuracy results for the Cue Flu Molecular Test?

The Cue Flu Molecular Test demonstrated 99% accuracy in clinical studies compared to FDA-cleared laboratory tests.

What is the stock symbol for Cue Health?

Cue Health's stock symbol is HLTH.

How does the Cue Flu Molecular Test work?

The Cue Flu Molecular Test uses a lower nasal swab and provides results digitally via Bluetooth to a mobile device in approximately 25 minutes.